The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.
Gilles A. Salles
Consultant or Advisory Role - Gilead Sciences; Janssen Research & Development; Roche
Honoraria - Mundipharma; Roche
Ajay K. Gopal
Research Funding - Janssen Research & Development
Peter Martin
Honoraria - Janssen Research & Development
Robert Marcus
No relevant relationships to disclose
Georg Hess
Honoraria - Janssen Research & Development
Pier Luigi Zinzani
No relevant relationships to disclose
Tahamtan Ahmadi
Employment or Leadership Position - Janssen Research & Development
Sen Hong Zhuang
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Ronald Levy
Consultant or Advisory Role - Janssen